Modeling of Regional Citrate Anticoagulation With a Dialysate Containing Calcium in Intermittent Hemodialysis (MARC)

Modeling of Regional Citrate Anticoagulation With a Dialysate Containing Calcium in Intermittent Hemodialysis

Sponsors

Lead Sponsor: University Hospital, Clermont-Ferrand

Source University Hospital, Clermont-Ferrand
Brief Summary

The primary purpose of this study is to validate a mathematical modeling of treatment by intermittent hemodialysis using regional citrate anticoagulation with a dialysate containing calcium

Detailed Description

The only visit to the study will be carried out during a usual dialysis session in the intensive care unit of Clermont-Ferrand University Hospital. In addition to the usual care, 2 blood samples will be taken from the blood circuit 1 hour after the start of the hemodialysis session by the nurse in charge of the patient.

Overall Status Not yet recruiting
Start Date November 2020
Completion Date December 2021
Primary Completion Date March 2021
Study Type Observational
Primary Outcome
Measure Time Frame
Ionized calcium level day 0
Total calcium level day 0
Total citratemia day 0
Enrollment 30
Condition
Intervention

Intervention Type: Other

Intervention Name: blood sampling

Description: 2 blood samples will be taken from the blood circuit 1 hour after the start of the hemodialysis session by the nurse in charge of the patient.

Arm Group Label: patients with hemodialysis

Eligibility

Sampling Method: Non-Probability Sample

Criteria:

Inclusion Criteria: - Major patient; - Man or woman ; - Treated with intermittent hemodialysis for chronic renal failure; - In whom intermittent hemodialysis with citrate solution for regional anticoagulation is indicated; - Affiliated with a social security scheme; - Having given a signed agreement after detailed explanation of the protocol on the basis of the information sheet and likely to comply with it Exclusion Criteria: - Severe hepato-cellular insufficiency (PT <50%, INR> 1.5 without anticoagulant); - Hemoglobin level <7 g / dL - Presenting a psychiatric pathology or cognitive impairment rendering him unable to give informed consent; - Persons under guardianship, curatorship, deprived of liberty or safeguard of justice - Pregnant or breastfeeding women - Patient's refusal to participate in the study.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
Julien Aniort Principal Investigator University Hospital, Clermont-Ferrand
Overall Contact

Last Name: Lise LACLAUTRE

Phone: +33473754963

Email: [email protected]

Location
Facility: Contact: CHU de Clermont-Ferrand Julien Aniort [email protected]
Location Countries

France

Verification Date

August 2020

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Arm Group

Label: patients with hemodialysis

Description: patient treated with intermittent hemodialysis for chronic renal failure

Acronym MARC
Study Design Info

Observational Model: Cohort

Time Perspective: Cross-Sectional

Source: ClinicalTrials.gov